Schroder Investment Management Group Acquires Shares of 261,201 The Chemours Company (NYSE:CC)

Schroder Investment Management Group bought a new position in shares of The Chemours Company (NYSE:CC - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 261,201 shares of the specialty chemicals company's stock, valued at approximately $4,393,000. Schroder Investment Management Group owned about 0.17% of Chemours as of its most recent SEC filing.

Several other large investors have also bought and sold shares of CC. Vanguard Group Inc. raised its position in shares of Chemours by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 15,223,961 shares of the specialty chemicals company's stock worth $257,285,000 after acquiring an additional 94,885 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Chemours by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company's stock valued at $50,646,000 after buying an additional 28,803 shares during the period. Norges Bank acquired a new stake in shares of Chemours in the 4th quarter valued at about $30,702,000. American Century Companies Inc. grew its stake in shares of Chemours by 7.6% in the 4th quarter. American Century Companies Inc. now owns 1,625,019 shares of the specialty chemicals company's stock valued at $27,463,000 after buying an additional 115,436 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Chemours by 6.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,302,272 shares of the specialty chemicals company's stock valued at $22,008,000 after buying an additional 73,220 shares during the period. 76.26% of the stock is owned by institutional investors.

Remove Ads

Chemours Price Performance

NYSE:CC traded down $1.17 during midday trading on Thursday, hitting $10.72. The company had a trading volume of 483,345 shares, compared to its average volume of 1,798,248. The stock's fifty day moving average price is $14.83 and its 200-day moving average price is $17.74. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The Chemours Company has a 52-week low of $9.33 and a 52-week high of $29.21. The company has a market capitalization of $1.60 billion, a PE ratio of 18.80 and a beta of 1.84.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. The business had revenue of $1.36 billion during the quarter, compared to analyst estimates of $1.37 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. As a group, research analysts expect that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were paid a $0.25 dividend. The ex-dividend date of this dividend was Friday, February 28th. This represents a $1.00 annualized dividend and a dividend yield of 9.33%. Chemours's payout ratio is presently 175.44%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on CC shares. Barclays reduced their target price on Chemours from $19.00 to $16.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 1st. BMO Capital Markets cut their price target on Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research note on Wednesday, February 19th. Truist Financial started coverage on shares of Chemours in a research report on Tuesday, January 28th. They set a "buy" rating and a $27.00 target price on the stock. Royal Bank of Canada reissued an "outperform" rating and set a $25.00 target price on shares of Chemours in a research report on Thursday, December 12th. Finally, Morgan Stanley dropped their target price on shares of Chemours from $25.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.56.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.